Gemfibrozil and repaglinide
- an interaction between gemfibrozil and repaglinide may occur when these drugs are administered concomitantly - in the situation the blood glucose-lowering effect of repaglinide may be markedly enhanced and prolonged. In light of this interaction, co-administration of gemfibrozil and repaglinide is contraindicated
- any change in repaglinide pharmacokinetics as a result of co-administration of gemfibrozil is likely to via inhibition of cytochrome P450 2C8. Thus other inhibitors of this enzyme e.g. trimethoprim, may also, if co-administered, enhance of effect of repaglinide
- it is not expected that other lipid-lowering agents will have a similar interaction with repaglinide
Reference:
- Current Problems in Pharmacovigilance (2003), 29, 6.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.